These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22930883)

  • 1. Drug therapy of inflammatory arthritis.
    Gullick NJ; Scott DL
    Clin Med (Lond); 2012 Aug; 12(4):357-63. PubMed ID: 22930883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of rheumatoid arthritis and ankylosing spondylitis.
    Braun J; Sieper J
    Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S146-7. PubMed ID: 19822062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy.
    Suh YS; Kwok SK; Ju JH; Park KS; Park SH; Yoon CH
    J Korean Med Sci; 2014 Jan; 29(1):38-42. PubMed ID: 24431903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs.
    Poddubnyy D; Song IH; Sieper J
    Clin Exp Rheumatol; 2009; 27(4 Suppl 55):S148-51. PubMed ID: 19822063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of golimumab in the treatment of arthritis.
    Fleischmann R
    Expert Opin Biol Ther; 2010 Jul; 10(7):1131-43. PubMed ID: 20504106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
    Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spondylarthropathies: options for combination therapy.
    van Tubergen AM; Landewé RB; van der Linden S
    Springer Semin Immunopathol; 2001; 23(1-2):147-63. PubMed ID: 11455853
    [No Abstract]   [Full Text] [Related]  

  • 9. Biologics, spondylitis and COVID-19.
    Rosenbaum JT; Hamilton H; Choi D; Weisman MH; Reveille JD; Winthrop KL
    Ann Rheum Dis; 2020 Dec; 79(12):1663-1665. PubMed ID: 32522741
    [No Abstract]   [Full Text] [Related]  

  • 10. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
    Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
    Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatoid arthritis: status of drug therapies.
    Moncur C; Williams HJ
    Phys Ther; 1995 Jun; 75(6):511-25. PubMed ID: 7770497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic Therapies for Rheumatologic and Autoimmune Conditions.
    Bays AM; Gardner G
    Med Clin North Am; 2016 Jul; 100(4):719-31. PubMed ID: 27235612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic management of the arthritic foot and ankle.
    DeJesus JM; Tsuchiya C
    Clin Podiatr Med Surg; 1999 Apr; 16(2):271-84. PubMed ID: 10331121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of rheumatoid arthritis.
    Handa R
    Natl Med J India; 2004; 17(3):143-51. PubMed ID: 15253402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic agents in rheumatoid arthritis: an update for managed care professionals.
    Agarwal SK
    J Manag Care Pharm; 2011; 17(9 Suppl B):S14-8. PubMed ID: 22073935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging treatments for rheumatoid arthritis.
    Schiff M
    Am J Med; 1997 Jan; 102(1A):11S-15S. PubMed ID: 9217554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases.
    Siebert S; Tsoukas A; Robertson J; McInnes I
    Pharmacol Rev; 2015; 67(2):280-309. PubMed ID: 25697599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
    Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
    Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.